n-Lorem Received $3 Million Gift to Support ASO Research and Discovery Efforts
SAN DIEGO, April 21, 2022–(BUSINESS WIRE)–n-Lorem, a non-profit foundation, today announced that the Wolverine Foundation has donated $3 million to support n-Lorem’s efforts to discover and deliver investigational antisense oligonucleotide (ASO) drugs for nano-rare patients (1 to 30 patients worldwide) for free and for life. As part of this collaboration, the Wolverine Foundation and its assembled team of renowned scientists and researchers will work with n-Lorem to accelerate the search and discovery of ASOs for allele-specific gene targets associated with neurodevelopmental diseases. As the collaboration progresses and research goals are achieved, n-Lorem could receive donations totaling up to $8.5 million to support ASO investigational drug development.
“n-Lorem’s research brings hope and greater understanding to patients with nano-rare diseases around the world,” said Wolverine Foundation fellows Rory Cunnane and Caroline Breed Cunnane. “Testing the effect of various allele-specific ASO knockdowns at the n-Lorem lab could pave the way for better treatment options for patients. This type of research is particularly close to our hearts, and we are excited to fund this new research project We “I am delighted to be working with Stan Crooke and his team at n-Lorem. We look forward to gaining new knowledge and funding additional research as we work to increase awareness of MAPK8IP3 and change lives.”
“On behalf of n-Lorem and our patients, I deeply appreciate the interest and commitment of the Wolverine Foundation. I have been impressed with the foundation’s leadership and scientific approach to supporting basic research and discovery of novel therapeutic approaches to treat neurodevelopmental diseases,” said Stanley T. Crooke, MD, Ph.D., Founder, CEO, and President of the n-Lorem Foundation. “We look forward to working closely with the Wolverine Foundation leadership team and the impressive array of academic researchers they have brought together.”
Watch: n-Lorem Foundation: Offering hope and help to nano-rare patients
Watch: The n-Lorem Foundation brings hope and treatment to a patient with a nano-rare disease
The Wolverine Foundation
The Wolverine Foundation serves to advance research and discover new therapeutic approaches to treat neurodevelopmental disease caused by genetic variations in the MAPK8IP3 gene. The Foundation aims to achieve these goals by supporting a team of researchers to study disease mechanisms and new therapeutic approaches associated with genetic variants of MAPK8IP3. The Foundation manages a diverse portfolio of research projects that encourages scientific collaboration to more directly link academic research, drug discovery and clinical development. The Foundation’s activities range from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials.
The n-Lorem Foundation is a nonprofit organization created to apply the efficacy, versatility, and specificity of antisense technology to provide charitable investigational antisense oligonucleotide (ASO) drugs to treat diagnosed nano-rare patients. with diseases that are the result of a single genetic defect unique to one or very few individuals. Nano-rare patients describe a very small group of patients (1 in 30 worldwide) who, due to their small numbers, have few or no treatment options. The n-Lorem Foundation was created to bring hope to these nano-rare patients by developing individualized ASO drugs, which are short strands of modified DNA that can specifically target the transcripts of a faulty gene to correct the ‘anomaly. The advantage of ASO investigational drugs is that they can be developed quickly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and has received over 130 treatment requests with over 50 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, MD, Ph.D., former President and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, has makes the company the leader in targeted RNA. therapeutic. follow us on Twitter, Facebook, LinkedIn, Youtube and instagram.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220421005202/en/
Amy Williford, Ph.D.
Senior Director of Communications and Donor Relations